Research identifies SARS-CoV-2 cavities as potential drug targets

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein has been the main target for the development of vaccines and other therapeutics needed to treat COVID-19 illness. New research published in the journal Future Medicine found the SARS-CoV-2 spike glycoprotein has druggable cavities with the best target being compatible with more than 1 billion compounds.

One compound known as Compound 38 had the highest affinity to a SARS-CoV-2 cavity and prevents viral entry. Results suggest it meddles with the interaction between the SARS-CoV-2 receptor binding domain and the human ACE2 receptor.

Compound 38 could be a potent inhibitor for blocking SARS-CoV-2 and may help shape future COVID-19 therapy.

Pockets of SARS-CoV-2 spike protein

SARS-CoV-2 Druggable Cavities. Image Credit:

How they did it

The researchers performed a computational analysis of the SARS-CoV-2 glycoprotein to search for potential binding sites. The search was facilitated by a program called CavityPlus which predicted the 3D structure of the spike glycoprotein. A SARS-CoV-2 cavity was considered ‘druggable’ if it was associated with a high drug score during pharmacophore modeling.

A virtual screening of a library with a large number of natural chemical compounds was used to improve the odds of finding a candidate that could target SARS-CoV-2 cavities. Autodock Vina was used to measure compounds with the highest affinities toward the druggable cavities.

SARS-CoV-2 cavity number 10 has the greatest ‘druggable’ potential

Forty-two SARS-CoV-2 cavities were identified in the spike glycoprotein with five being potentially druggable. When searching the SARS-CoV-2 spike glycoprotein, the team found one druggable cavity next to the receptor-binding domain of the S glycoprotein. The druggable cavity number 10 had the highest drug score during pharmacophore modeling and was used for the rest of the study.

Of more than 1 billion compounds, 410 were potential matches for drug cavity number 10.

Compound 38 blocks SARS-CoV-2 infection

Of the 410 chemical compounds tested, compound 38 had the highest affinity for the drug cavity because of interactions with amino acids G381, E516, L517, L518, H519, R567, D571, and T572 in the virus glycoprotein. Amino acid residues E516, L517, and D571 had the closest contact with the cavity.

The compound 38 helped block viral entry with no significant toxicity. The finding was confirmed when observed an increase in affinity when substituting nitrogen N4 with CCN and H functional groups of the compound to the receptor.

Two derivative compounds (H and CCN) showed promising interaction energies when functional group N4 of compound 38 was substituted with the functional groups. This indicates the minor impact of this residue on compound 38 affinity to SARS-coV-2 S glycoprotein,”

Journal reference:
Jocelyn Solis-Moreira

Written by

Jocelyn Solis-Moreira

Jocelyn Solis-Moreira graduated with a Bachelor's in Integrative Neuroscience, where she then pursued graduate research looking at the long-term effects of adolescent binge drinking on the brain's neurochemistry in adulthood.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Solis-Moreira, Jocelyn. (2021, June 21). Research identifies SARS-CoV-2 cavities as potential drug targets. News-Medical. Retrieved on July 29, 2021 from

  • MLA

    Solis-Moreira, Jocelyn. "Research identifies SARS-CoV-2 cavities as potential drug targets". News-Medical. 29 July 2021. <>.

  • Chicago

    Solis-Moreira, Jocelyn. "Research identifies SARS-CoV-2 cavities as potential drug targets". News-Medical. (accessed July 29, 2021).

  • Harvard

    Solis-Moreira, Jocelyn. 2021. Research identifies SARS-CoV-2 cavities as potential drug targets. News-Medical, viewed 29 July 2021,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Researchers examine the effectiveness of the Pfizer-BioNTech COVID-19 vaccine in reducing household transmission